Exelixis Reports Strong Q1, Authorizes New $750M Buyback, Advances Key Oncology Pipeline

summarizeSummary

Exelixis announced robust first-quarter 2026 financial results, authorized an additional $750 million stock repurchase program, and provided extensive updates on its zanzalintinib clinical development, including new trial initiations and regulatory progress.

check_boxKey Events

• Strong Q1 2026 Financial Results

  Reported total revenues of $610.8 million (up 10% year-over-year) and GAAP diluted EPS of $0.79 (up 43.6% year-over-year), while maintaining full-year 2026 guidance. This follows the concurrent 10-Q filing.

• New $750 Million Stock Repurchase Program Authorized

  The Board of Directors authorized an additional $750 million for share repurchases through December 31, 2027. This program follows the expected completion of the prior $750 million program in May 2026.

• Zanzalintinib NDA Accepted by FDA

  The New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer was accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.

• Expanded Clinical Development for Zanzalintinib

  Initiated a Phase 2 trial (STELLAR-201) in recurrent meningioma, announced plans for a Phase 2 trial (STELLAR-202) in lung cancer, and an expansion cohort in a Phase 1b/2 study (STELLAR-002) in prostate cancer. Additionally, collaborator Merck initiated the LITESPARK-034 Phase 3 trial.

auto_awesomeAnalysis

This filing highlights a strong operational and strategic quarter for Exelixis. The significant double-digit growth in revenue and EPS demonstrates solid execution of its commercial strategy. The authorization of a new $750 million share repurchase program, following the expected completion of a prior program, signals management's confidence in the company's valuation and commitment to returning capital to shareholders. Furthermore, the comprehensive updates on the zanzalintinib pipeline, including FDA acceptance of an NDA and the initiation of multiple new clinical trials, underscore the company's progress in expanding its oncology franchises and future growth drivers. Investors should view these developments as a strong positive signal for the company's near-term performance and long-term pipeline potential.